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Background: Some patients with depression do not respond to first and second line conventional antidepressants
and are therefore characterised as suffering from treatment refractory depression (TRD). On-going psychosocial
stress and dysfunction of the hypothalamic-pituitary-adrenal axis are both associated with an attenuated clinical
response to antidepressants. Preclinical data shows that co-administration of corticosteroids leads to a reduction in
the ability of selective serotonin reuptake inhibitors to increase forebrain 5-hydroxytryptamine, while co-administration
of antiglucocorticoids has the opposite effect. A Cochrane review suggests that antiglucocorticoid augmentation of
antidepressants may be effective in treating TRD and includes a pilot study of the cortisol synthesis inhibitor,
metyrapone. The Antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study) is a multicentre
randomised placebo controlled trial of metyrapone augmentation of serotonergic antidepressants in a large
population of patients with TRD in the UK National Health Service.
Methods/design: Patients with moderate to severe treatment refractory Major Depression aged 18 to 65 will be
randomised to metyrapone 500 mg twice daily or placebo for three weeks, in addition to on-going conventional
serotonergic antidepressants. The primary outcome will be improvement in Montgomery-Åsberg Depression Rating
Scale score five weeks after randomisation (i.e. two weeks after trial medication discontinuation). Secondary outcomes
will include the degree of persistence of treatment effect for up to 6 months, improvements in quality of life and also
safety and tolerability of metyrapone. The ADD Study will also include a range of sub-studies investigating the
potential mechanism of action of metyrapone.
Discussion: Strengths of the ADD study include broad inclusion criteria meaning that the sample will be
representative of patients with TRD treated within the UK National Health Service, longer follow up, which to our
knowledge is longer than any previous study of antiglucocorticoid treatments in depression, and the range of
mechanistic investigations being carried out. The data set acquired will be a rich resource for a range of research
questions relating to both refractory depression and the use of antiglucocorticoid treatments.
Trial registration: Current Controlled Trials: ISRCTN45338259; EudraCT Number: 2009-015165-31.
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Depression is a common disorder, affecting some 10% of
the population [1]. It is rated by the Disease Control
Priorities Project as one of the leading medical contribu-
tors to the global burden of disease [2]. It can become
long-lasting and may recur frequently. Depression has a
large negative impact on the quality of life of service
users and their carers. It is associated with high morbid-
ity (depression has been identified as one of the leading
causes of work days lost and working-age adults receiv-
ing disability payments in the UK) [3] and mortality,
through suicide and increased deaths from cardiovascu-
lar disease [4]. Clinical guidelines recommend the use of
antidepressant medication for the treatment of a moder-
ate to severe depressive episode [1,5]. Antidepressant
drugs have established efficacy versus placebo in clinical
trials, however, in naturalistic settings many patients
have unsatisfactory outcomes. The large pragmatic
STAR*D study conducted in the USA showed that even
with protocol driven treatment, first line therapy with a
selective serotonin reuptake inhibitor (SSRI: citalopram)
in over 2500 patients was associated with remission in
only 28%, and response (defined as a 50% decrease in
symptom scores) in less than 50% of patients [6]. Further,
second line treatment in the STAR*D study with an alter-
native antidepressant was associated with an even lower
remission rate of 20-25% [7]. Much of the burden is con-
sequent upon this treatment refractory depression (TRD).
Clinical response to antidepressant treatment may be
influenced by a number of factors, but an inadequate
neurochemical response is one likely mechanism of non-
response. The majority of antidepressants, on chronic ad-
ministration, elevate forebrain levels of 5-hydroxytryptamine
(serotonin, 5-HT). The clinical importance of this is sup-
ported by the fact that acute depletion of tryptophan
(the precursor of 5-HT) can lead to the rapid return of
depressive symptoms in patients treated with antidepres-
sants [8,9]. There is a long-held notion that life events and
lack of social support predict worse treatment outcomes
in patients with depression [10]. The mechanism of this
may relate to the hypothalamic-pituitary-adrenal (HPA)
axis. It is well established from animal and human studies
that glucocorticoids influence multiple aspects of 5-HT
neurotransmission (including the sensitivity of 5-HT1A
autoreceptors and postsynaptic 5-HT receptor efficacy
[11-14] that are postulated to be central to the antidepres-
sant mechanism of action [15]). Furthermore, dys-
regulation of the HPA axis can reduce the effects of
antidepressants in the frontal cortex. Implantation of
corticosteroid releasing pellets in rodents to induce an
HPA axis dysregulation has been shown to attenuate the
ability of antidepressants to elevate forebrain 5-HT levels
[16]. Interestingly, there is also increasing evidence that
antiglucocorticoid treatments have the opposite effect byenhancing the forebrain 5-HT response to antidepres-
sants [17]. This suggests that reducing normal physio-
logical levels of glucocorticoid receptor activation can
increase the elevation of 5-HT in response to SSRIs. These
data suggest a potential mechanism by which anti-
glucocorticoid strategies can enhance the clinical effective-
ness of antidepressants in clinical practice.
HPA axis abnormalities are often demonstrated in pa-
tients with mood disorders. HPA axis dysregulation in
depression is often characterised, particularly in those
with melancholic symptoms, by a flattened cortisol diur-
nal rhythm with elevated trough levels of cortisol [18]
and by attenuated negative feedback effects of corticoste-
roids on adrenocorticotrophin hormone (ACTH) and cor-
tisol release [19]. There is increasing evidence that shows
such dysregulation is associated with poor prognosis, in-
cluding non-response to antidepressants and future re-
lapse [20-26]. Further, a Cochrane review demonstrated
the efficacy of antiglucocorticoid augmentation of anti-
depressants in patients with depression with the largest
effect size seen with metyrapone [27], a cortisol synthe-
sis inhibitor which crosses the blood–brain barrier.
There have been several open or open-label, including
randomised, studies of metyrapone augmentation of
antidepressants, showing efficacy in treatment-resistant
depression [28-32]. In addition a successful proof-of-
concept double blind, placebo controlled randomised
study has been conducted by Jahn and colleagues [33]
in a centre in Germany, with 63 depressed inpatients.
Patients were all on a serotonergic antidepressant and
were randomised to add-on treatment with metyrapone
(1 g/day for 3 weeks) or placebo. The primary outcome
measure was the percentage of responders (defined by a
set improvement on the Hamilton depression rating
scale) 5 weeks after randomisation (i.e. 2 weeks after
cessation of metyrapone or placebo augmentation).
Patients receiving metyrapone were significantly more
likely to respond than those receiving placebo, with an
effect size of d = 0.63. Kaplan-Meier analysis revealed a
faster response with metyrapone, which was well toler-
ated and without serious side-effects.
Aims
The primary aim of the “Antiglucocorticoid augmentation
of anti-Depressants in Depression” (ADD) study is to
examine the efficacy and safety of metyrapone augmenta-
tion of serotonergic antidepressants in a randomised con-
trolled trial (RCT) in patients with Major Depression who
have not responded to at least two courses of antidepres-
sants in their current episode. The study extends research
in this area by exploring the translatability of the proof of
concept study described above [33] to an outpatient, pri-
mary and secondary care, UK National Health Service
(NHS) population. To date, all published studies of the
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short treatment periods of 1-3 weeks [27], which can ap-
pear counter-intuitive in such a potentially chronic condi-
tion. However, evidence suggests that the clinical effects of
antiglucocorticoids on HPA axis function persist after their
prescription has ceased [34,35]. The persistence of effects
on depressive symptoms and quality of life will therefore
be examined in the ADD study for around 6 months after
stopping metyrapone treatment compared with the 2 week
follow-up period of Jahn and colleagues [33].
The exact mechanism by which metyrapone may en-
hance antidepressant efficacy is unknown. A secondary
aim of the ADD study is to explore the impact of
metyrapone on HPA axis function and the hypothesis
that metyrapone leads to altered neural responsiveness
to glucocorticoids with an increase in the frontocortical
5-HT response to antidepressants. In addition, a number
of studies in sub-samples, drawn from the main RCT
population, will also be undertaken using electroencepha-
lographic (EEG) and functional magnetic resonance im-
aging (fMRI) techniques, assessment of neuropsychological
function, and genetic variability to address this mechanis-
tic aim. Only the elements of the study relating to the full
RCT sample (efficacy and safety measures and HPA axis
function) will be described in detail here. The sub-studies
are, however, detailed in Table 1. The description of the
protocol below is consistent with the SPIRIT (Standard
Protocol Items: Recommendations for Interventional Trials)
2013 recommendations (see http://www.spirit-statement.
org/spirit-statement/).
Methods/design
Study design
The ADD study is a multicentre parallel group, double-
blind, randomised, placebo-controlled superiority trial of
augmentation of serotonergic antidepressants with me-
tyrapone in patients with moderate to severe depression
who have failed to respond to adequate trials of at least
two antidepressants in their current episode.
Study population
The initial study aim was to recruit 190 patients. How-
ever due to initial slow recruitment rates after discussion
with the funder, sponsor and the independent Data
Monitoring and Ethics Committee, a revised target of
140 was agreed by accepting a reduction in power of the
study from 90% to 80% on the primary outcome mea-
sure (see below). These patients will be recruited from
primary and secondary care settings.
Inclusion criteria
 Diagnostic and Statistical Manual of Mental
Disorders – Fourth Edition (DSM-IV) [61] definedmajor depressive episode assessed using the
Structured Clinical Interview for DSM (SCID)
research version [62].
 Hamilton Depression Rating Scale -17 item (HDRS17)
[63] score of ≥ 18 at week -2 and 0 (see below).
 Massachusetts General Hospital Treatment
Resistant Depression (MGH-TRD) staging score of
2-10 as a measure of treatment refractoriness [64].
This cut off is based on MGH-TRD scores seen in
primary and secondary care, but short of tertiary
care, in the UK NHS [65].
 Single agent or combination antidepressant treatment
which includes a serotonergic drug (a selective
serotonin reuptake inhibitor, a tertiary amine tricyclic,
venlafaxine, duloxetine or mirtazapine). At the point
of randomisation, patients must have been on their
current antidepressant medication, at the current
dose, for a minimum of four weeks.
 Aged between 18-65. An upper age limit is included to
reduce rates of physical health comorbidities that could
complicate decisions around the safety of prescription
of a drug (metyrapone) that may lower cortisol levels.
Exclusion criteria
 Other DSM-IV axis I diagnosis, other than an anxiety
disorder considered to be secondary to a primary
diagnosis of depression, confirmed using SCID.
 Physical co-morbidity that would make metyrapone
inappropriate, including untreated hypothyroidism,
disorders of steroid production, cardiac failure,
angina, myocardial infarction in the last 3 years and
renal failure.
 Pregnancy or breastfeeding.
 Use of medication that would interfere with
metyrapone.
 Dependence on alcohol or other drug(s) in the past
12 months, and/or current harmful use of such
substances (defined as meeting SCID criteria for
harmful use or dependence).
 Recent participation in a research study that could
interfere with results.
Recruitment
Patient identification will occur across two hubs of the
UK NIHR Mental Health Research Network - the North
East with centres in Newcastle and Teesside and the
North West with Manchester as the centre - and in
the West Yorkshire Comprehensive Local Research
Network – with centres in Leeds and Bradford. Potential
participants will be identified through routine clinic ap-
pointments at study sites and Participant Identification
Centres that will include Primary Care and Community
Mental Health Teams.
Table 1 Sub-studies: data collected and rationale
Sub- study Data collected Rationale Participants
Neuropsychological
function
CANTAB spatial working memory
(SWM) task [36].
The neuropsychological tasks have chosen on
the basis of their known sensitivity to cortisol
and/or 5-HT manipulations. For example
SWM has been shown to be sensitive to
corticosteroid manipulations in healthy
controls and patients [37-39]. The FEERT,
ECMT and affective go/no-go tasks, on the
other hand have strong evidence for
sensitivity to 5-HT manipulations [40-42],
while episodic verbal memory, as tested with
the VTL) is sensitive to both corticosteroid
and 5-HT manipulations [43-45]. Changes in
performance of the tasks following
metyrapone treatment will help identify
whether any improvements with the
treatment may be associated with changes in
HPA axis function and/or 5-HT neurotransmission.
80 patients, equal numbers
from each treatment arm.
50 patients recruited in
Newcastle and 30
in Manchester.
Patients – week 0 and 5 Verbal Learning Test (VTL)
comprising neutral, positive and
negative emotional words with
immediate and delayed recall
and recognition trails.
Healthy Controls – week 0
55 healthy controls.
Object-Location Memory (OLM)
paradigm [46].
Digit Span – forward and backward.
Attentional Network Test (ANT) [47].
Facial Emotional Expression Recognition
Test (FEERT) [48].
Emotional Categorisation and Memory
test (ECMT) [48].
Affective Go/No Go Task [49].
EEG: Treatment response
prediction
Alpha power. This sub-study will utilise a range of EEG
variables with an evidence base for predicting
response to monoaminergic antidepressants
[50]. The LDAEPs have been shown to
differentially predict response to serotonergic
versus noradrenergic antidepressants [51]. We
predict that the relationship between clinical
response and LDAEP measurement will be
consistent with serotonergic enhancement by
metyrapone.
50 patients, equal numbers
from each treatment arm,
recruited in Newcastle.Alpha hemispheric asymmetry.
Patients – week 0 and 5
Theta power localised to
anterior cingulate.Healthy Controls – week 0 25 healthy controls.
Loudness dependency of auditory
evoked potentials (LDAEPs).
EEG: Neural correlates
of emotional processing
and memory
Emotional source memory task
(ESMT) [52].
The ESMT task will examine the neural
correlates of emotional episodic memory in
patients and the effects of metyrapone
treatment. This will supplement the
information provided in the VTL in the
neuropsychological sub-study described above.
50 patients, equal numbers
from each treatment arm,
recruited in Newcastle.
Putative EEG measure of long-term
potentiation (LTP) [55]. 25 healthy controls.
The putative LTP measure has previously been
shown to be impaired in depressed patients
[53] and LTP is known to be sensitive to
corticosteroids in animals [54]. We predict that
treatment with metyrapone will normalise
potential impairments in this measure in the
patient cohort.
Patients – week 0 and 5
Healthy Controls – week 0
Newcastle fMRI sub-study Facial emotional processing
task (FEPT) [56].
FEPT allows investigation of a functional
cortical network involved in the processing
of emotions and emotional responses. It
supplements information obtained using the
FEERT in the neuropsychological sub-study
described above and enable localisation of any
effects seen. Likewise the EEMET will
supplement the information provided in the VTL.
30 patients from NE Hub -
equal number from each
treatment arm.Patients – week 0 and 5
Emotional episodic memory
encoding task (EEMET) [57].Healthy Controls – week 0 15 healthy controls matched
for age, handedness and IQ.
Manchester fMRI
sub-study
Neural correlates of episodic
and working memory.
The episodic memory task will involve
encoding and recall of neutral and emotionally
valenced pictures, while the working memory
task will utilise the N-back task. This will further
supplement the data obtained in the
neuropsychological sub-study.
30 patients from NW Hub -
equal number from each
treatment arm.
Patients – week 0 and 5 Hydrocortisone pharmacoMRI [58].
30 healthy matched controls.
For the pharmacoMRI, at week 0 patients
receiving metyrapone will receive a 100 mg
hydrocortisone bolus and those receiving
placebo saline. Healthy controls will be
randomised to hydrocortisone or saline. At
week 5 all patients will receive hydrocortisone.
We predict that blunted acute hippocampal
Healthy Controls – week 0
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Table 1 Sub-studies: data collected and rationale (Continued)
responses to hydrocortisone pre-treatment will
normalise after metyrapone, but not placebo,
treatment.
Genotyping We will look for an association between
treatment outcome, its predictors and genetic
polymorphisms and also for genetic influences
on brain information processing (for example
brain derived neurotropic factor (BDNF) and
corticotrophin releasing factor (CRF) variants
and hippocampal response to hydrocortisone
in Manchester/amygdala response to emotional
faces in Newcastle). We will also investigate the
DNA samples for rare genetic variants (e.g.
copy number variations). We will determine our
candidate gene list based on previous candidate
gene association studies and recent novel
findings from genome-wide association studies
with major depressive disorder and by considering
relevant genes for the function of the HPA axis.
All patients and healthy
controls approached for
specific consent to provide
a DNA sample.
Patients and Controls
Note, all the patients will be recruited from the main ADD study RCT with additional inclusion criteria of being aged 18-60. To assist in interpretation of the data
an additional cohort of healthy controls will be recruited who are currently psychiatrically well, confirmed through SCID interview and HDRS17 < 5 and being on
no current psychotropic medication. Exclusion will also include presence of a past history of psychiatric illness or a history of psychiatric illness in a first degree
relative. The controls will be matched with the patients for age (+/- 5 years), gender, handedness and IQ (+/- 7 points as assessed using the National Adult
Reading Test [59]). Handedness will be assessed for all subjects taking part in EEG and fMRI studies (using the Edinburgh Handedness Inventory [60]). Only right
handed patients and healthy controls will be included in the fMRI sub-studies described below.
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Participants will continue their existing antidepressant
regime. Randomisation will be in a 1:1 ratio of me-
tyrapone to matched placebo using permuted block ran-
domisation, stratified by inclusion in mechanistic studies
sub-sample, level of care setting (i.e. primary or second-
ary care) and by centre. A randomisation code will be
computer generated by the Newcastle Clinical Trials
Unit and coded packs of the study drug and matched
placebo will be produced, according to the random-
isation schedule. All medication will be supplied from
a single central pharmacy with all participants and
study staff blinded to treatment allocation. To ensure
blinding the metyrapone will be over-encapsulated
and the placebo will be visually identical. Participants
in the treatment arm will receive study drug
(metyrapone 500 mg or placebo) twice daily, prescribed
in the morning and at noon, for 21 days. Adherence to
medication will be assessed using measures of 11-
deoxycortisol as described below under “HPA axis
Assessment”.
Apart from treatment with the experimental inter-
vention, all other treatments will remain under the
control of the patient’s normal treating psychiatrist
and/or general practitioner. However, the patients’ cli-
nicians will be encouraged to avoid changes to medi-
cations between enrolment (week -2) and the primary
outcome time point (week +5) unless there is a com-
pelling clinical reason to alter treatment. All current
medication will be recorded at all follow up time
points.Objectives
Primary clinical objective
 The primary objective is to determine whether
metyrapone (500 mg twice a day) for 21 days is
efficacious in augmenting conventional serotonergic
antidepressants in TRD in a UK NHS primary and
secondary care setting. This to be assessed by
Montgomery-Åsberg Depression Rating Scale
(MADRS) [66] scores two weeks post treatment
(week +5 from randomisation), comparing patients
treated with metyrapone to those treated with
placebo.
Secondary clinical objectives
 To determine the clinical effect size at two weeks
post-completion of treatment of a three-week course
of metyrapone (vs placebo) augmentation of
antidepressants in depressed patients who have
failed to respond to at least two courses of
antidepressants, in primary care and psychiatric
outpatient clinics in the UK.
 To assess whether the response is sustained for up
to 21 weeks post cessation of metyrapone.
 To assess whether metyrapone augmentation
improves patients’ quality of life using the self-
completed EuroQol EQ-5D instrument
(http://www.euroqol.org/).
 To assess the tolerability and safety of metyrapone
augmentation in a large sample taken from a
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and primary care patients with TRD.Mechanistic objectives related to the full RCT sample
 To assess whether metyrapone changes patients’
HPA axis function.
 To assess whether changes in HPA axis function
with metyrapone persist after stopping metyrapone.
 To assess whether the change in HPA axis function
correlates with clinical response.
 To assess whether baseline HPA axis function
predicts clinical response.Study schedule
All assessments will be undertaken by trained research
personnel under the supervision of the clinically trained
principle investigators (INF, RHMW, SW, IMA, AOH,
HCRG, PMH, TH, AJL).ble 2 Schedule of assessments
Enrolment Randomisation
me point Week-2 Week 0
sessment of eligibility √
formed Consent √
sessment of baseline characteristics –
wMood questionnaire*
√
perimental Intervention
sessment of depression
verity – HDRS171
√ √
sessment of Clinical symptoms –
ADRS2, CAS3, BDI4,STAI5, YMRS6
√
sessment of Quality of Life – EQ-5D √
sessment of side effects – TSES7 √
sessment of side effects and
verse events – self report
√
icide risk assessment √ √
egnancy Test if indicated √ √
sessment of concomitant medication √ √
easurement of HPA axis function
AR plus 11 pm saliva sample)
√
ysical observations** √***
ood Tests – U&E’s, cortisol √****
See text under “Screening Visit” for description of NewMood questionnaire deta
- Physical observations comprised sitting and standing pulse and blood, and pre
* - Screening physical observations also included height and weight.
** – Screening blood tests also including thyroid function tests, liver function test
DRS17 Hamilton Depression Rating Scale – 17 item.
ADRS Montgomery-Asberg Depression Rating Scale.
AS Clinical Anxiety Scale.
DI Beck Depressive Inventory.
TAI State Trait Anxiety Inventory.
MRS Young Mania Rating Scale.
SES Toronto Side Effects Scale.Screening visit (week -2)
Written informed consent will be obtained and study eli-
gibility determined. Height, weight and safety measure-
ments (see Table 2 for details) will be recorded. Baseline
blood tests including urea and electrolytes, cortisol, thy-
roid function test, liver function tests, full blood count
and β-human chorionic gonadotropin (if indicated) will
be taken. Background factors, personality, and childhood
adversity and life events will be assessed between re-
cruitment and randomisation, using the NewMood back-
ground questionnaire [67] given to patients to complete
and return at the next visit. This questionnaire includes
the Big Five Inventory 44 personality questionnaire [68],
a negative life events questionnaire adapted from the list
of Life Threatening Experiences [69], the Social Circum-
stances Questionnaire, which is an adaptation of the So-
cial Support Questionnaire [70] as used in the NewMood
study [67], the Childhood Trauma Questionnaire [71] and
the Ruminative Responses Scale [72]. Depression severity
will be determined using the HDRS17, which will be ratedFollow up
Week
1
Week
2
Week
3
Week
4
Week
5
Week
8
Week
16
Week
24
√ √ √ √ √
√ √ √ √ √
√ √ √
√ √ √ √ √ √ √ √
√ √ √ √ √ √
√ √ √
√ √ √ √ √ √ √ √
√ √
√ √
√ √
ils.
ssure respiration rate.
s and full blood count.
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the MADRS [66].
Randomisation visit (week 0)
Subjects will excluded if their HDRS17 has dropped
below 18 or if there has been any change in their current
antidepressant medication (drug or dose). Otherwise
study medication will be supplied to commence the fol-
lowing day.
Follow –up
Data will be collected at weeks +1, +2, +3 (end of active
treatment period), +4, +5 (primary outcome time point),
+8, +16 and +24 from the date medication was started
(+/- 2 days). The week +2 and +4 visits can be com-
pleted by telephone. Details of the assessments at each
time point are described in Table 2. Depression severity
will be assessed using the MADRS administered by
trained members of the research team at time +3, +5,+8,
+16 and + 24 weeks. The primary outcome measure will
be the change in MADRS from week 0 to +5 weeks. The
MADRS has preferable psychometric properties and
higher sensitivity to change than other depression rating
scales [74] and was associated with the largest effect size
in the Jahn study [33]. Additional secondary outcome
measures of symptomatology (Clinical Anxiety Scale
(CAS) [75], Beck Depressive Inventory (BDI) [76], State
Trait Anxiety Inventory (STAI) [77] and Young Mania
Rating Scale (YMRS) [78]) will be conducted at the same
time points as described for the MADRS. Quality of life
will be assessed using the self-completed EuroQol EQ-
5D instrument (http://www.euroqol.org/) and tolerability
using the Toronto Side Effects Scale (TSES) [79].
Metyrapone treatment potentially engenders hypo-
cortisolaemia with manifestations including a risk of
postural hypotension, hyperkalaemia and hypernatremia.
Therefore, safety assessments will include serum cortisol
measures at week +1 as well as measuring sitting and
standing blood pressure and urea and electrolytes at
weeks +1 and +5.
HPA axis assessment
Cortisol levels to determine the cortisol awakening re-
sponse (CAR) [80] will be obtained at the start of treat-
ment (week 0) and then again at +3 and +5 weeks for all
patients. This entails participants collecting 5 ml of sal-
iva by passive drool [81] into a plastic collecting tube on
wakening and then again at 15 minute intervals for a
further hour. A total of five samples will be collected on
each occasion either the day before or day after the
planned study visit. Participants will also be asked to col-
lect a saliva sample for cortisol assay at 11 pm the night
before each of the three CAR assessments. In addition
to collection of saliva samples, participants will completea brief questionnaire relating to the nature and quality
of sleep the night before the CAR assessment.
In addition to the saliva samples, serum samples will
be taken at -2, +1 and +5 weeks for analysis of cortisol
precursors and metabolites. Metyrapone administration
has previously been shown to cause an increase in levels
of ACTH, DHEA and 11-deoxycortisol together with an
increase in the cortisone:cortisol ratio [33,82]. The in-
crease in 11-deoxycortisol between weeks -2 and +1 will
be used as a measure of adherence to medication since
this has been shown to be highly sensitive to treatment
with metyrapone [33,82].
Sample size, power and effect size
The primary outcome measure is change in MADRS be-
tween weeks 0 and +5. The effect size for this measure
in the Jahn study [33] was 0.63. The study has been
powered around the more conservative moderate effect
size of 0.5 which, assuming a post-intervention standard
deviation of 12 points [33], corresponds to a six point
difference on the MADRS. An achieved sample size of
85 per group is required to detect effect size of 0.5 with
90% power, assuming alpha = 0.05. Allowing for 10% at-
trition during the trial, the original aim was to random-
ise 95 per group; 190 in total. However, as described
above the recruitment target has been modified
accepting a power of 80%, requiring a sample size of 63
per group. Again allowing for 10% attrition during the
trial, we aim to randomise 70 per group; 140 in total.
Statistical analysis
A full Study Analysis Protocol will be drawn up prior to
completion of the study and breaking of the study blind.
There is no planned interim analysis and no “stopping
rules” for the study as a whole. Individual patients will
be withdrawn from the study medication if it appears
that to continue would be deleterious for their mental
health or safety. This can be determined by the patient,
the treating clinician and/or the research team and will
be supported by the use of the MADRS particularly if
there is an increase in the score for question 10 “suicidal
thoughts”, or a lack of improvement in total MADRS
score.
The primary outcome will be an intention to treat ana-
lysis of variance of the MADRS scores of the two treat-
ment groups (metyrapone and placebo) at +5 weeks
covarying for baseline MADRS. The persistence of
change in the MADRS score will then be assessed using
repeated measures analysis of variance utilising data
from all time points. The change and persistence of the
change in other clinical and quality of life measures will
be examined using the same methods. Additional sec-
ondary outcomes will include rates of response (defined
as a 50% or greater reduction in MADRS score) and
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With regard to the mechanistic objectives, the study
will examine whether treatment with metyrapone leads
to a change in HPA axis function (assessed by examining
the CAR and 11 pm cortisol measures) and whether
changes in HPA axis function, compared to baseline, are
seen two weeks post treatment. Both baseline HPA axis
function and change in function with treatment will be
assessed to see if they predict clinical response to
metyrapone defined by the change in MADRS between
week 0 and week +5, in an exploratory analysis.
Status of the study
The study was registered on 21/12/2009 (ISRCTN45338259)
under the public title “Antiglucocorticoid augmentation of
antiDepressants in Depression: the ADD study”. Clinical
Trial Authorisation was given by the Medicines and
Healthcare products Regulatory Agency (MHRA:
EudraCT: 2009-015165-31). Ethical approval was granted
by the Sunderland Local Research Ethics Committee (REC
Ref No. 10/H0904/9) on 22/04/2010. Recruitment com-
menced in February 2011.
Discussion
The ADD Study is the largest RCT of antiglucocorticoid
treatment of Major Depression in the UK and one of the
largest worldwide. In addition it is novel in its length of
follow up and in its inclusion of a range of mechanistic
studies exploring how such treatments might work.
Compared to many previous studies, including a rela-
tively large proof of concept study of metyrapone aug-
mentation of conventional antidepressants [33], the
ADD study is recruiting from a broad population of pa-
tients including those from both primary and secondary
care. Inclusion criteria have intentionally been kept
broad and exclusion criteria to a minimum in order to
explore the efficacy of metyrapone treatment in as real
world a setting as possible. This means, for example, pa-
tients with significant suicidal ideation, who are often
excluded from RCTs in depression, will be included in
the ADD Study.
The patients included in the ADD study will be ex-
tremely well characterised at base line in relation to a
number of factors know to relate to TRD as well as in-
fluencing HPA axis function. For example personality
traits are associated with refractoriness to treatment in
patients with depression [83] and the ADD study will
characterise personality using the Big Five Inventory 44
personality questionnaire [68]. Further, given the impact
of life events and childhood trauma on HPA axis func-
tion and potential vulnerability to depression [84,85],
these factors will also be well characterised using the
negative life events questionnaire [69], the SocialCircumstances Questionnaire [70] and the Childhood
Trauma Questionnaire [71].
The dosing schedule for metyrapone that has been se-
lected for the ADD Study is 500 mg twice a day admin-
istered in the morning and at noon. The total daily dose
matches that given in previous studies [33]. The ration-
ale for the timing of administration is to coincide with
the portion of the day associate with the highest cortisol
concentrations. While the ADD Study is not including
direct measures of metyrapone plasma concentrations in
patients, measurement of plasma 11-deoxycortisol after
1 week’s treatment will serve as a sensitive assessment of
both compliance and pharmacodynamics effect of the
treatment. Previous data shows that metyrapone admin-
istration is associated with highly significant increases in
11-deoxycortisol [33,82] due to its effect of blocking
11β-hydroxylase.
The degree of treatment refractoriness of patients will
be carefully assessed using the MGH-TRD staging scale
[64]. There is a lack of consensus as to which staging
scale for refractory depression should be used in studies.
We have chosen the MGH-TRD scale due to its ease of
use especially taking into account scoring for dose opti-
misation and augmentation/combination treatment. We
have chosen a minimum MGH-TRD score of 2 for in-
clusion. Use of a single antidepressant at an effective
dose scores 1 point and hence this minimum represents
a failure to respond to at least 2 antidepressants given
usual UK practice in primary care of not augmenting or
combining medications for depression until after this
stage [1]. Beyond this point in the treatment algorithm
for individual patients there is great divergence in prac-
tice with patients being referred to secondary care at dif-
ferent stages by individual clinicians. The maximum
MGH-TRD score for inclusion has been set as 10. In
practice this means 5-6 trials of different antidepressants
allowing for dose optimisation and augmentation/com-
bination strategies used for some of these trials. Use of
electroconvulsive therapy scores 3 points in the MGH-
TRD scale. As such this in itself is not an exclusion cri-
terion in the ADD Study. However since most patients
receiving ECT will have also had at least a couple of an-
tidepressants, often with dose optimisation and augmen-
tation, in practice few patients treated with ECT have a
score under the maximum cut off of 10.
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